Martin Schleef
Overview
Explore the profile of Martin Schleef including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shankar R, Schmeer M, Schleef M
Methods Mol Biol
. 2024 May;
2786:303-319.
PMID: 38814401
A plasmid production process has been established to manufacture plasmid DNA at a large scale in High-Quality grade. This is used as a starting material to produce mRNA vaccines for...
2.
Izco M, Schleef M, Schmeer M, Carlos E, Verona G, Alvarez-Erviti L
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111717
The development of effective disease-modifying therapies to halt Parkinson's disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS)...
3.
Lock D, Monjezi R, Brandes C, Bates S, Lennartz S, Teppert K, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36096530
Background: There is an increasing demand for chimeric antigen receptor (CAR) T cell products from patients and care givers. Here, we established an automated manufacturing process for CAR T cells...
4.
Schmeer M, Schleef M, Shankar R, Kobelt D, Walther W
Methods Mol Biol
. 2022 Jun;
2521:317-328.
PMID: 35733006
Plasmid DNA in any form (plasmid DNA, minicircle, miniplasmid) does experience renewed and increasing attention for use in gene therapy and DNA vaccination. For such applications, stability analyses and quality...
5.
Prommersberger S, Monjezi R, Shankar R, Schmeer M, Hudecek M, Ivics Z, et al.
Methods Mol Biol
. 2022 Jun;
2521:25-39.
PMID: 35732991
Development and application of chimeric antigen receptor (CAR) T cell therapy has led to a breakthrough in the treatment of hematologic malignancies. In 2017, the FDA approved the first commercialized...
6.
Shankar R, Schafer N, Schmeer M, Risse J, Friehs K, Schleef M
Microb Cell Fact
. 2021 Sep;
20(1):190.
PMID: 34579706
No abstract available.
7.
Shankar R, Schaffer N, Schmeer M, Risse J, Friehs K, Schleef M
Microb Cell Fact
. 2021 Aug;
20(1):171.
PMID: 34454498
Background: The use of bovine-origin ribonucleases has been part of the standard protocol for plasmid DNA purification. As the field of gene therapy now enters the clinical stage, such enzymes...
8.
Izco M, Blesa J, Schleef M, Schmeer M, Porcari R, Al-Shawi R, et al.
Mol Ther
. 2019 Sep;
27(12):2111-2122.
PMID: 31501034
The development of new therapies to slow down or halt the progression of Parkinson's disease is a health care priority. A key pathological feature is the presence of alpha-synuclein aggregates,...
9.
Holstein M, Mesa-Nunez C, Miskey C, Almarza E, Poletti V, Schmeer M, et al.
Mol Ther
. 2018 Mar;
26(4):1137-1153.
PMID: 29503198
The Sleeping Beauty (SB) transposon system is a non-viral gene delivery platform that combines simplicity, inexpensive manufacture, and favorable safety features in the context of human applications. However, efficient correction...
10.
Schmeer M, Buchholz T, Schleef M
Hum Gene Ther
. 2017 Aug;
28(10):856-861.
PMID: 28826233
Plasmid DNA is currently gaining increasing importance for clinical research applications in gene therapy and genetic vaccination. For direct gene transfer into humans, good manufacturing practice (GMP)-grade plasmid DNA is...